“I think oftentimes people think this is just a radiology procedure that is rather benign. That’s really the role of the oncology nurse, just to be [an educator], support, emotional support, and a coach,” Lisa Parks, MS, APRN-CNP, ANP-BC, nurse practitioner in hepatobiliary surgery at The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center in Columbus, Ohio, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about what oncology nurses should know about transarterial chemoembolization administration and their role surrounding that procedure. This episode is part of a series about non-IV chemotherapy administration; the others are linked below.  You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD), which may be applied to the oncology nursing practice or treatment ILNA categories, by listening to the full recording and completing an evaluation at myoutcomes.ons.org by November 10, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center’s Commission on Accreditation.  Learning outcome: The learner will report an increase in knowledge related to transarterial chemoembolization.   Episode Notes  Complete this evaluation for free NCPDComplete this evaluation for free NCPD.  Oncology Nursing Podcast episodes about non-IV chemotherapy administration:  Episode 271: Intraventricular and Intrathecal Administration: The Oncology Nurse’s Role  Episode 265: Intravesical Administration: The Oncology Nurse’s Role  Episode 252: Intraperitoneal Administration: The Oncology Nurse’s Role  Oncology Nursing Forum articles:  Symptom Distress in Patients With Hepatocellular Carcinoma Toward the End of Life  Living With Hepatocellular Carcinoma Near the End of Life: Family Caregivers’ Perspectives  ONS Chapters  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From Today’s Episode  “So, TACE was commonly used to treat liver metastatic cancers, primarily metastatic colon cancer, until research showed that some of these cancers were not responding to TACE. Therefore, it is no longer really used in metastatic colon cancer. TACE is used in hepatocellular cancer. It also was used more than 10 years ago to treat metastatic neuroendocrine cancers. But recent research has showed that neuroendocrine cancers respond to this embolization without the use of chemotherapy. By eliminating chemotherapy, we also eliminate the potential for side effects.” TS 3:29  “TACE, or TAE, is usually completed more than once in the course of a patient’s treatment. Depending on the tumor burden of the liver, the procedure can be segmentally completed on a liver lobe, or you can do the procedure on the right lobe and then follow-up treatment in about six weeks in the left lobe.” TS 5:45  “This is something that isn’t even really taught in medical school. So it’s really important to understand that even though this is a postprocedural side effect, there are certain things that you have to be aware of. So, the most common side effect that you will see is right upper-quadrant pain, and this is very common. And if the left side of the liver has received the therapy, this pain can radiate to the epigastric area and the patient will